Related by context. All words. (Click for frequent words.) 75 K ras mutations 73 KRAS mutations 72 EGFR mutation 71 KRAS status 71 VKORC1 71 NSCLC tumors 70 EGFR mutations 70 gefitinib Iressa 70 K ras 70 K RAS 70 Her2/neu 70 T#I [002] 69 breast cancer subtypes 69 mutated K ras 69 BRAF mutation 69 prostate cancer CaP 69 urothelial carcinoma 69 metastatic lymph nodes 69 HER2 expression 69 p# biomarker 69 Estrogen Receptor 68 Haptoglobin 68 PCa 68 FDG PET 68 prognostic markers 68 Epidermal Growth Factor Receptor 68 co receptor tropism 68 unresectable tumors 68 pancreatic adenocarcinoma 68 NPM1 mutation 68 UGT#A# 68 gene amplification 67 microsatellite instability 67 MammaPrint R 67 FDG-PET/CT 67 BRAF V#E mutation 67 antiangiogenic therapy 67 tumor subtypes 67 neoadjuvant therapy 67 metastatic neuroendocrine tumors 67 immunohistochemical 67 KRAS mutation status 67 predictive biomarker 67 Lymph node 67 prostate carcinoma 67 EGFr 67 DNA methylation patterns 67 sipuleucel T 67 ImmuKnow 67 nonsmall cell lung cancer 67 liver metastasis 67 Pertuzumab 67 trastuzumab Herceptin ® 67 immunohistochemical analysis 66 percutaneous biopsy 66 Histologic 66 sentinel lymph node biopsy 66 RRM1 66 prognostic marker 66 K ras gene 66 NPM1 66 HER2 overexpression 66 nodal metastasis 66 gastric adenocarcinoma 66 mucinous 66 #F FDG PET 66 colorectal liver metastases 66 EGFR inhibitors 66 Cardiotoxicity 66 HER2 positivity 66 antitumor effect 66 histological subtype 66 premalignant lesions 66 EGFR tyrosine kinase inhibitors 66 Lenalidomide 66 eTag assays 66 chemosensitivity 66 epithelial tumors 66 Sentinel Lymph Node Biopsy 66 chemoresistant 66 F FDG PET 66 TOP2A 66 sarcosine 66 EGFR mutation status 66 ADAMTS# 66 urine cytology 66 Trastuzumab 66 tumor histology 66 malignant pleural mesothelioma 66 florbetaben 66 Oncotype 66 KRAS gene 66 Sipuleucel T 66 prognostically 66 thalidomide Thalomid 65 TMPRSS2 ERG 65 malignant nodules 65 ASCUS 65 PIK3CA 65 methylation markers 65 TPMT 65 histopathological 65 B7 H3 65 CIN2 + 65 squamous cell lung cancer 65 K ras mutation 65 metaplasia 65 antibody titer 65 transrectal ultrasound guided 65 prostate cancer PCa 65 VeriStrat 65 molecular biomarkers 65 advanced adenomas 65 Tumor Response 65 Squamous 65 ERCC1 65 renal carcinoma 65 ADVEXIN therapy 65 FLT3 65 thyroglobulin 65 MAGE A3 ASCI 65 KRAS gene mutations 65 Velcade bortezomib 65 histopathologic examination 65 EUS FNA 65 myelofibrosis polycythemia vera 65 cTnI 65 Xelox 65 KRAS oncogene 65 somatic mutations 65 HNSCC 65 imatinib resistance 65 dasatinib Sprycel 65 medically inoperable 65 troponins 65 T SPOT.TB 65 genomic alterations 65 Histological 65 cetuximab Erbitux 65 HAAH 65 Doxil ® 65 HBsAg 65 poor metabolizers 65 immunochemical 65 estrogen receptor ER 65 Septin 9 65 adjuvant chemotherapy 65 adjuvant radiotherapy 65 recurrent glioblastoma multiforme 65 prognostic indicator 65 metastatic RCC 65 mCRC patients 65 CYP#C# [001] 65 predictive biomarkers 65 ZOLINZA 65 histopathologic 64 Prognostic factors 64 HER2 receptor 64 ELISpot 64 hepatoma 64 NMIBC 64 gastric carcinoma 64 Immunohistochemical analysis 64 H pylori 64 HER2 gene 64 microRNA expression 64 EGFR TKI 64 imatinib Gleevec 64 Cytogenetic 64 prognostic variables 64 CYP#D# gene 64 Erlotinib 64 HER2 positive cancers 64 OnDose TM 64 PROLARIS 64 PITX2 methylation 64 vemurafenib 64 resected pancreatic cancer 64 MSH2 64 sorafenib Nexavar 64 gastrointestinal stromal tumors GIST 64 CYT# potent vascular disrupting 64 S. maltophilia 64 follicular lymphoma FL 64 prognostic biomarker 64 breast carcinoma 64 prognostic indicators 64 androgen independent 64 precancer 64 malignant lesions 64 GIST tumors 64 D Dimer 64 MET amplification 64 haematopoietic 64 Gastrointestinal Stromal Tumors 64 PKCi 64 Bevacizumab 64 erlotinib Tarceva ® 64 Naive Patients 64 Surgical resection 64 neoadjuvant treatment 64 genotypic resistance 64 antiangiogenic agent 64 relapsed SCLC 64 ALK inhibitors 64 bevacizumab Avastin 64 peritoneal carcinomatosis 64 neoadjuvant chemotherapy 64 metastatic malignant 64 PARP inhibition 64 cisplatin resistant 64 diagnostic biomarker 64 HERmark 64 PITX2 64 completely resected 64 Hepatocellular Carcinoma HCC 64 RT qPCR 64 PTPN# 64 serologic tests 64 AGTR1 64 Pemetrexed 64 GSTP1 64 trastuzumab DM1 T DM1 64 RQ PCR 64 preoperative staging 64 ADPKD 64 genomic biomarker 64 histologic 64 BRAF mutations 64 thyroid nodules 64 Panitumumab 64 NMP# 64 serum biomarkers 64 Leukemias 64 PROSTVAC TM 64 chromosomal mutations 64 anti angiogenic agents 64 pT2 64 Microalbuminuria 64 TGFBR1 * 6A 64 adjuvant radiation 64 metastatic castration resistant 64 morphologic 64 APOE genotype 63 galiximab 63 Zolinza 63 STRIDE PD 63 Cervista HPV HR 63 Gram stain 63 gene rearrangements 63 MyVax R 63 biochemical recurrence 63 micrometastases 63 cytoreductive nephrectomy 63 castrate resistant 63 pharmacogenetic testing 63 fosbretabulin 63 HIV HCV coinfected 63 bronchoalveolar lavage 63 Her2 63 CINQUIL 63 pharmacodynamic parameters 63 immunochemical fecal occult 63 serologic 63 HLA DQ2 63 liposomal amphotericin B 63 miRview ™ squamous 63 gastrointestinal stromal tumors GISTs 63 differentially expressed genes 63 tumorigenicity 63 colorectal cancer CRC 63 WT1 63 hormone receptor negative 63 metastatic renal cell carcinoma 63 anti JCV antibodies 63 castration resistant prostate cancer 63 pertuzumab 63 germline mutations 63 ovarian carcinoma 63 perfusion MRI 63 riociguat 63 ToGA 63 C Reactive Protein 63 prognostic significance 63 EGFR expression 63 differentiate squamous 63 Nexavar sorafenib 63 IGF IR 63 prostate cancer CRPC 63 duplex ultrasonography 63 alkaline phosphatase ALP 63 pCR 63 ABCB1 63 KRAS wild 63 prophylactic cranial irradiation 63 genes CYP#C# 63 IRX 2 63 KRAS 63 ELISPOT 63 Akt activation 63 metastatic lesions 63 Nilotinib 63 AlloMap 63 Circulating Tumor Cells 63 Xanafide 63 murine models 63 seminoma 63 bladder carcinoma 63 urothelial cancer 63 adenocarcinomas 63 Pralatrexate 63 CYP#D# genotype 63 stratifying patients 63 pretargeting 63 ImmuKnow assay 63 plasma kallikrein 63 mutational status 63 LRP5 63 hepatocellular carcinomas 63 colorectal carcinoma 63 Trastuzumab DM1 63 flavopiridol 63 multi analyte 63 DNA methylation markers 63 microRNA biomarkers 63 core needle biopsies 63 specific antigen PSA 63 refractory prostate cancer 63 hormone refractory 63 LHRH receptor positive 63 Deforolimus 63 Oncotype DX colon cancer 63 endoscopic ultrasonography 63 MammaPrint 63 differentiated thyroid 63 Corus CAD 63 Outpatient Setting 63 postoperative radiotherapy 63 tumor necrosis 63 Gleevec resistant 63 BEXXAR Therapeutic Regimen 63 HER2/neu 63 relapsed ovarian cancer 63 obstructive coronary artery 63 Dasatinib 63 pre malignant lesions 63 mapatumumab 63 gemcitabine carboplatin 63 sunitinib Sutent 63 MGd 63 empiric therapy 63 5q deletion 63 olaparib 63 PROCHYMAL 63 HERmark assay 63 ELISPOT assay 63 circulating endothelial cells 63 Zevalin consolidation 63 FDG PET imaging 63 castrate resistant prostate cancer 63 invasive lobular 63 adjuvant therapies 63 metastatic colorectal 63 hematopoietic cancers 63 clinicopathological 63 Subgroup analysis 63 gemcitabine Gemzar 63 malignant ascites 63 APTIMA HPV 63 IDH mutations 63 immunohistochemistry IHC 63 curative resection 63 Mutational 63 NMP# assay 63 taxane therapy 63 Immunohistochemical 63 EGFR mutation positive 63 PNH patients 63 Tyrosine Kinase Inhibitor 63 cediranib 63 FGFR1 63 calcineurin inhibitors 63 antiangiogenic agents 63 gp# vaccine 63 molecular subtypes 63 chlamydial 63 bone scintigraphy 63 SLNB 63 C. pneumoniae 63 mutated KRAS 63 mRCC 63 preoperative chemotherapy 63 guaiac 63 CD#c 63 multivariate analyzes 63 ErbB2 positive 63 prospective multicentre 63 resectable 63 carcinoid tumors 63 miRNA expression 63 Neoadjuvant 63 sDNA 63 sentinel node 63 CDH1 63 vitro assay 63 erlotinib Tarceva 62 ALK mutations 62 subgroup analyzes 62 selenium supplementation 62 Clusterin 62 PROSTVAC VF 62 extramedullary 62 tigecycline 62 Trofile TM 62 gastrointestinal stromal tumors 62 promoter methylation 62 cytoreductive surgery 62 CellSearch ™ 62 abnormal cytology 62 BRAF V#E 62 IMA# 62 biomarker 62 spiral computed tomography 62 bevacizumab Avastin ® 62 Nesiritide 62 choroidal vasculopathy 62 baseline LDH 62 Adjuvant chemotherapy 62 Antitumor Activity 62 histone deacetylases 62 activating mutations 62 standard chemotherapy regimen 62 virologic responses 62 Prognostic 62 Gefitinib 62 Roche AmpliChip 62 oral squamous cell 62 Aflibercept 62 elevated LDH 62 hepatocellular cancer 62 multigene expression test 62 antiangiogenesis 62 advanced adenoma 62 pharmacogenetic 62 pituitary adenomas 62 cMET 62 HIV tropism 62 Glufosfamide 62 methylation patterns 62 biomarker assay 62 Li Fraumeni 62 Immunohistochemical staining 62 beta1 integrin 62 locoregional recurrence 62 druggable targets 62 pharmacogenetic tests 62 kidney urologic 62 IRESSA 62 HER2 positive metastatic breast 62 Neuvenge 62 endocrine therapies 62 trabectedin 62 QTc prolongation 62 allogeneic HSCT 62 PCR assay 62 mutant BRAF 62 biopsied tissue 62 VerifyNow 62 immunohistochemical staining 62 clade B 62 ovarian malignancy 62 cardiac repolarization 62 crizotinib PF # 62 Histopathologic 62 locoregional 62 Papillary 62 Allogeneic 62 metastatic prostate 62 bortezomib Velcade 62 EGFR inhibition 62 situ LCIS 62 5alpha reductase 62 nonalcoholic steatohepatitis NASH 62 surgically resectable 62 histologic diagnosis 62 hormone deprivation 62 biomarker identification 62 inhibit EGFR 62 p# activation 62 Prostate Cancer Progression 62 micrometastasis 62 lung metastasis 62 HSCT 62 E. faecalis 62 immunostaining 62 Fc gamma receptor 62 CYP#C# [002] 62 prostate specific 62 HER3 62 isotype 62 pretreatment serum 62 SPINK1 62 PCA3 gene 62 cytokeratin 62 biliary tract cancer 62 Ceflatonin 62 carcinoid 62 hormone receptor status 62 pancreatic lung 62 complete cytogenetic response 62 FGFR3 62 FCGR3A 62 breast carcinomas 62 Vidaza azacitidine 62 EndoTAGTM 1 62 Bisphosphonate 62 Hormone Refractory Prostate Cancer 62 liver metastases 62 pancreatic ductal adenocarcinoma 62 APOL1 62 Fulvestrant 62 gene polymorphisms 62 BCL#A 62 BRCA deficient 62 azacytidine 62 NAbs 62 fluoropyrimidine 62 Epratuzumab 62 EGFR protein 62 carcinoids 62 invasive carcinoma 62 trastuzumab Herceptin 62 delafloxacin 62 Temsirolimus 62 conserved sequences 62 nodal dissection 62 CCX# 62 aT cell 62 Renal Cell Carcinoma 62 precursor lesions 62 Adjuvant therapy 62 OncoVEX GM CSF 62 clinically localized prostate 62 LVNC 62 elacytarabine 62 invasive lobular carcinoma 62 adjuvant therapy 62 PathFinderTG 62 tipranavir ritonavir 62 Hormone receptor 62 Preclinical Study 62 RAS mutations 62 Pegylated Interferon 62 Hepatocellular Carcinoma 62 pain palliation 62 clinicopathologic 62 hypermethylated 62 HCV replicon 62 Randomized trials 62 ccRCC 62 AGHD 62 XYOTAX TM 62 chlamydial infection 62 malignant lymphoma 62 Adjuvant Chemotherapy 62 lymphoid malignancies 62 serum PSA 62 Pegylated 62 endometrial hyperplasia 62 nosocomial pneumonia 62 tumor recurrence 62 liver transplant recipients 62 invasive candidiasis 62 BRIM3 62 KRAS BRAF 62 AST ALT 62 Cloretazine 62 Gamma Imaging BSGI 62 chemotherapeutic regimen 62 carcinoembryonic antigen 62 selective modulator 62 humanised antibody 62 mitochondrial toxicity 62 malignant transformation 62 TroVax ® 62 concurrent chemoradiation 62 p# antigen 62 CCR5 inhibitor 62 EML4 ALK 62 clinicopathological features 62 Malignant Melanoma 62 GISTs 62 qRT PCR 62 benign moles 62 pT3 62 posaconazole 62 immunomodulation 62 Disease Progression 62 candidemia 62 tumor subtype 62 PCNSL 62 sentinel lymph node 62 gastric carcinomas 62 ImmuKnow R 62 tumor biopsies 62 Non inferiority 62 NKX#.# 62 VerifyNow P#Y# 62 Factor Receptor 62 Septin9 62 EGFR pathway 62 CSF biomarkers 62 viral kinetics 62 human leukocyte antigen 62 nodal metastases 62 EGS# 62 lactate dehydrogenase LDH 62 Adenomas 62 Hurthle cell 62 metastatic gastric 62 Oncotype DX Recurrence Score 62 IDH1 mutation 62 multivariate regression analysis 61 coinfected patients 61 neuroblastoma tumors 61 TNF blocker therapy 61 MAGE A3 61 NF kB pathway 61 lymph node metastasis 61 eIF 4E 61 Degarelix 61 malignant growths 61 OnDose 61 histologies 61 IGFBP2 61 prospectively defined 61 A3 adenosine receptor 61 chemokine receptor 61 renal tumors 61 Virologic 61 epithelial ovarian cancer 61 Pharmacogenetic 61 Treg cell 61 Subgroup analyzes 61 antiproliferative effects 61 genotypic 61 ixabepilone 61 sarcomatoid 61 mTOR inhibitors 61 elevated CRP 61 breast cancer metastasis 61 genomewide 61 RT PCR assay 61 lymph node metastases 61 Kaplan Meier analysis 61 Lp PLA 2 61 antigen PSA 61 Ki# 61 troponin T 61 OncotypeDX 61 Follicular Lymphoma 61 mtDNA mutations 61 molecular abnormalities 61 TP# mutations 61 Aplidin 61 pharmacokinetic interactions 61 T1a 61 Interferon Beta 61 HBeAg negative 61 Dendreon Provenge 61 sorafenib tablets 61 epigenetic therapies 61 BCR ABL mutations 61 renal cell carcinomas 61 oncological outcomes 61 Histologically 61 monogenic 61 nonmetastatic 61 malignant polyps 61 molecular determinants 61 decitabine 61 Immunotherapeutic 61 BRCA mutations 61 GRNCM1 61 recurrent NSCLC 61 miRview TM mets 61 cTnT 61 IgG antibody 61 adenomatous polyps 61 minimally symptomatic 61 histone deacetylase inhibitor 61 Cystatin C 61 multivariate Cox 61 Stage IIIb 61 precancerous condition 61 standard chemotherapy regimens 61 miRview mets 61 Hexvix 61 dasatinib 61 genetic biomarkers 61 biologic plausibility 61 ALK gene 61 putative biomarkers 61 malignant prostate 61 enzastaurin 61 virotherapy 61 neoadjuvant 61 hematological parameters 61 GRASPA ® 61 modifier genes 61 Virulizin ® 61 pegylated liposomal doxorubicin 61 SCCHN 61 resected tumors 61 BRAF inhibitor 61 lung adenocarcinoma 61 peginterferon alpha 61 cardiac troponin T 61 TIMP 1 61 N glycan 61 HIF PH inhibitors 61 axillary lymph node 61 Enzastaurin 61 genetic polymorphisms 61 glioblastoma tumors 61 pretransplant 61 angiographically 61 renal artery stenosis 61 EGFR blockers 61 anti angiogenic agent 61 prostate adenocarcinoma 61 distant metastasis 61 pancreatic carcinoma 61 Alequel 61 Immunohistochemistry 61 Telatinib 61 PDGF receptor 61 therapeutic regimens 61 p# mutation 61 Mammostrat 61 Anticalins ® 61 androgen receptor AR 61 Mucosal 61 surrogate endpoint 61 CBLC# 61 haematologic 61 transient elastography 61 specific antigen 61 prostatic adenocarcinoma 61 clonogenic 61 ERBB2 61 adjuvant trastuzumab 61 PSADT 61 seminomas 61 Mutation Analysis 61 HER2 amplification 61 cancer mCRC 61 BladderChek 61 colorectal adenocarcinoma 61 acinar cells 61 pulmonary metastases 61 antiviral therapy 61 annexin 61 Survival Benefit 61 chemopreventive agent 61 metastatic malignant melanoma 61 Bucindolol 61 Antigens 61 cardiac troponin 61 kinase inhibition 61 allogeneic transplant 61 Targeted Therapy 61 pharmacodynamic biomarkers 61 BRCA mutation carriers 61 CT Colonography 61 CYP#C# genotype 61 thiopurine drugs 61 Genotypic 61 HGPIN 61 HLA DR4 61 Prognostic Value 61 intestinal biopsy 61 preclinically 61 CCR9 61 vWD 61 clusterin 61 fibrotic disease 61 squamous 61 excisional biopsy 61 basal cell carcinoma BCC 61 Troponin T 61 Torisel 61 INCB# [001] 61 SSc 61 Pharmacokinetic PK 61 prostate tumor 61 radiolabeled TM# 61 Cytoxan 61 nonmelanoma skin cancers 61 CD# expression [001] 61 activating mutation 61 HGS ETR2 61 pelvic lymphadenectomy 61 localized renal 61 Prostate Specific Antigen 61 N. gonorrhoeae 61 Combidex 61 FGFR2 61 molecular biomarker 61 pancreatic islet cell 61 Onconase 61 plasma lipid 61 Bortezomib 61 sentinel nodes 61 cell lysate 61 pathologic examination 61 NovoTTF 61 chemoradiation therapy 61 M. pneumoniae 61 etiologic 61 EBV infection 61 genomic biomarkers 61 sensitivity specificity 61 viral tropism 61 molecularly targeted 61 axillary dissection 61 ADAM# 61 depsipeptide 61 Gastric Cancer 61 leiomyomas 61 thymidylate synthase TS 61 histologic findings 61 non squamous NSCLC 61 SERMs 61 cervical lymph nodes 61 MTHFR 61 FGFs 61 oral Xeloda 61 Pharmacodynamic 61 Solorel TM 61 Afatinib 61 non squamous 61 Solid Tumors 61 stage IIIA 61 papillary renal cell carcinoma 61 EGFR tyrosine kinase inhibitor 61 imatinib therapy 61 p# biomarkers 61 malignant ovarian 61 HoFH 61 deCODE ProstateCancer TM 61 ZNF# 61 transcriptomic 61 TMPRSS2 ERG fusion 61 anti androgens 61 VFEND 61 Chlamydia psittaci 61 Advanced Melanoma 61 transurethral resection 61 Alemtuzumab 61 Vectibix monotherapy 61 FGFR2 gene 61 atypical hyperplasia 61 anti CD3 61 allogeneic stem cell 61 HCV antibody 61 myeloperoxidase 61 virulence genes 61 MGMT gene 61 sustained virologic response 61 relapsed ALL 61 Situ Hybridization 61 Vitaxin 61 serous ovarian cancer 61 intact parathyroid hormone 61 Natalizumab 61 BrachySil TM 61 COX2 61 Pooled Analysis 61 Metastases 61 Aurora Kinase 61 immunological responses 61 PTEN gene 61 GAMMAGARD 61 SNP rs# [002] 61 neovascular 61 replicon 61 serum antibody 61 EGFR TKIs 61 pharmacodynamic PD 61 pharmacokinetic PK profile 61 underwent resection 61 alteplase 61 liposomal doxorubicin 61 Chemokine Receptor 61 EpCAM 61 RhuDex R 61 abacavir Ziagen 61 quantitative PCR 61 inactivating mutations 61 histologic subtype 61 Panzem 61 LungExpress Dx 61 Ranolazine 61 PSMA ADC 61 recurrent GBM 61 XmAb# 61 NCCN guidelines 61 Romiplostim 61 beta carotene supplementation 61 MTT assay 61 mutated KRAS gene 61 fine needle aspiration 61 IDH1 mutations 61 p# mutations 61 Single Nucleotide Polymorphisms 61 cytologic 61 RAR beta 61 Platinol ® cisplatin 61 XELOX 61 immunocompetent 61 MIF protein 61 nonnucleoside reverse transcriptase inhibitors 61 CMV disease 61 HER2 61 Hematopoietic 61 imatinib resistant 61 Vorinostat 61 endosonography 61 neratinib 61 operable breast cancer 61 prognostic biomarkers 61 lobular carcinoma 61 Prospective Randomized 61 colorectal tumor 60 Randomized clinical trials 60 rituximab Rituxan 60 Atypical Hemolytic Uremic Syndrome 60 Nedd4 60 KRAS mutant 60 ganetespib 60 p# MAPK 60 MGUS 60 BRAF V# mutation 60 MyVax 60 antiplatelet therapies 60 pelvic ultrasound 60 platelet reactivity 60 mutational analysis 60 perfusion abnormalities 60 thyroid carcinoma 60 Renal Cell Carcinoma RCC 60 adenomatous 60 alpha fetoprotein AFP 60 c KIT 60 histologically 60 K#N 60 BEXXAR 60 Imatinib 60 Aliskiren 60 iniparib 60 CP CPPS 60 TLR antagonist 60 LRAT 60 HLA DRB1 * 60 acetabular fractures 60 serologic testing 60 Hedgehog Pathway Inhibitor 60 Taxotere ® 60 MSMB 60 AEG# 60 miRview meso 60 HLA B 60 independent prognostic marker 60 AVOREN 60 lymphovascular invasion 60 EGFR activating mutations 60 SELDI TOF MS 60 mTOR mammalian target 60 Cytochrome P# 60 small molecule activators 60 hA# 60 transgene expression 60 lymphadenectomy 60 Severe Sepsis 60 ovarian pancreatic 60 telomerase inhibition 60 ritonavir boosted 60 Metastatic Prostate Cancer 60 virological response 60 mSEPT9 60 hyperplastic polyps 60 FLT3 mutations 60 T SPOT.TB test 60 miRview squamous 60 multiplex PCR 60 SMAD4 60 colon carcinoma 60 multivariate logistic regression